title: Dendritic cell-based nanovaccines for cancer immunotherapy.
abstract: Cancer immunotherapy critically relies on the efficient presentation of tumor antigens to T-cells to elicit a potent anti-tumor immune response aimed at life-long protection against cancer recurrence. Recent advances in the nanovaccine field have now resulted in formulations that trigger strong anti-tumor responses. Nanovaccines are assemblies that are able to present tumor antigens and appropriate immune-stimulatory signals either directly to T-cells or indirectly via antigen-presenting dendritic cells. This review focuses on important aspects of nanovaccine design for dendritic cells, including the synergistic and cytosolic delivery of immunogenic compounds, as well as their passive and active targeting to dendritic cells. In addition, nanoparticles for direct T-cell activation are discussed, addressing features necessary to effectively mimic dendritic cell/T-cell interactions.
authors.affiliation: Department of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
authors.forename: Leonie E
authors.initials: LE
authors.lastname: Paulis
authors.forename: Subhra
authors.initials: S
authors.lastname: Mandal
authors.forename: Martin
authors.initials: M
authors.lastname: Kreutz
authors.forename: Carl G
authors.initials: CG
authors.lastname: Figdor
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D036103:Nanotechnology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines